eISSN: 2299-0054
ISSN: 1895-4588
Videosurgery and Other Miniinvasive Techniques
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2019
vol. 14
 
Share:
Share:
Original paper

Gastric gastrointestinal stromal tumors: clinical features and short- and long-term outcomes of laparoscopic resection

Maciej Stanek
,
Magdalena Pisarska
,
Dorota Budzyńska
,
Anna Rzepa
,
Michał Pędziwiatr
,
Piotr Major
,
Andrzej Budzyński

Videosurgery Miniinv 2019; 14 (2): 176–181
Online publish date: 2019/03/26
Article file
- gastric.pdf  [0.09 MB]
Get citation
 
PlumX metrics:
 

Introduction

Gastrointestinal stromal tumors (GISTs) were first classified as a distinct type of neoplasm in 1983 [1]. Although they are relatively rare, they are considered the most prevalent mesenchymal neoplasms of the digestive tract [2]. Their most common location is the stomach, but they can also occur in other parts of the digestive system as well as outside of it (urinary bladder, extraperitoneal space) [3]. They are characterized by considerable clinical diversity, ranging from small, localized, slow-growing lesions to very aggressive tumors that already have massive metastases upon diagnosis [4, 5].

The treatment of initially resectable tumors involves their removal with a margin of the surrounding healthy tissue [6]. The removal of the regional lymphatic tissue is not required, as metastasis of GISTs to lymph nodes is rarely observed [7].

In the last three decades, laparoscopy has played an increasingly important role in the treatment of both benign and malignant tumors. The first report about use of this approach for removal of a gastric GIST comes from 1992 [8]. It was a small tumor with very low potential for malignancy. In the following years, the treatment of these tumors by laparoscopy gained increasing support. Although minimally invasive techniques are currently recognized as effective and validated treatment for small gastric GIST, the role of laparoscopy is not yet established, especially in the institutions that have less experience in minimally invasive surgery [9].

Aim

The aim of the study was to evaluate the outcomes of laparoscopic treatment of gastric gastrointestinal stromal tumors compared to the results obtained in a group of patients treated with conventional surgery.

Material and methods

Design

A retrospective analysis of data collected for a group of patients treated for gastric GIST at the 2nd Department of General Surgery at the Jagiellonian University in Krakow in the period from 2002 to 2017 was performed. The study group included patients with an initially resectable tumor that was confirmed to be a gastric stromal neoplasm upon histopathological examination of the surgical specimen. Patients who underwent neoadjuvant treatment with tyrosine kinase inhibitors, those who at the time of the diagnosis had distant metastases, and patients with an additional malignant neoplasm were excluded from the study.

The analyzed medical data included clinical and pathomorphological features of removed tumors, perioperative parameters as well as short- and long-term results of surgical treatment.

Patients were divided into two groups – those who were treated laparoscopically (group 1) and patients who underwent conventional surgery (group 2). Factors affecting the short- and long-term outcomes were compared between the two groups.

During the pre-operative period, a computed tomography (CT) scan and a gastroscopy with a sample for histopathological examination were performed for each patient. The tumors’ potential for malignancy was determined according to the ESMO 2012 guidelines. The largest dimension of the GIST measured during the histopathological examination was recorded as the tumor’s diameter. Blood loss and operative time were established on the basis of documentation prepared by surgeons and anesthesiologists participating in the operation. Surgery-related risk was estimated using the American Society of Anesthesiologists (ASA) scale, while the post-operative complications were evaluated according to the Clavien-Dindo classification [10].

Material

In the analyzed period, 68 patients (47 women and 21 men) were treated for gastric GISTs at the 2nd Department of General Surgery at the Jagiellonian University in Krakow. The mean age of the patients was 63.75 years.

Laparoscopy was performed for 46 of the patients. The remaining 22 patients underwent conventional surgery (these patients were operated on in the first few years of the analyzed period). The demographics of the patients are presented in Table I, whereas the type of surgery is shown in Table II. Only the tumor characteristics according to the ESMO classification including size were significantly different.

Table I

Demographics of patients

ParameterTotal n (%)Group 1 n (%)Group 2 n (%)P-value
Number of patients684622
Females, n (%)47 (69.1)33 (71.7)14 (63.6)0.4987
Males, n (%)21 (30.9)13 (28.3)8 (36.4)
Age, median (IQR)66.5 (55.5–74.5)67 (59–75)65 (55–70)0.5597
BMI, median (IQR)27.7 (25.2–32.4)27.8 (23.9–33.1)27.2 (26.2–31.2)0.9802
ASA 1, n (%)1 (1.5)1 (2.2)0.0276
ASA 2, n (%)42 (61.8)33 (71.7)9 (40.9)
ASA 3, n (%)25 (36.7)12 (26.1)13 (59.1)
Location, n (%):0.6814
 Cardia11 (16.2)6 (13.0)5 (22.7)
 Lesser curvature15 (22.1)10 (21.7)5 (22.7)
 Greater curvature34 (50.0)25 (54.4)9 (40.9)
 Antrum8 (11.7)5 (10.9)3 (13.7)
Histological subtypes, n (%):0.6613
 Spindle cell46 (67.6)30 (65.2)16 (72.7)
 Epithelioid10 (14.7)8 (17.4)2 (9.1)
 Mixed12 (17.6)8 (17.4)4 (18.2)
ESMO risk classification, n (%):0.0326
 Very low14 (20.6)11 (23.9)3 (13.6)
 Low34 (50.0)23 (50.0)11 (50)
 Moderate12 (17.6)10 (21.7)2 (9.1)
 High8 (11.8)2 (4.4)6 (27.3)
Diameter, median (IQR) [cm]4.35 (3.55–5.5)4 (3.5–5.5)4.75 (4–7)0.0319
Table II

Type of surgery

Laparoscopic treatment (group 1):
 Wedge gastric resection using stapler19
 Local transmural gastrectomy27
Open treatment (group 2):
 Wedge gastric resection using stapler9
 Local transmural gastrectomy7
 Distal gastrectomy4
 Proximal gastrectomy1
 Total gastrectomy1

Ethics

The study was approved by the Ethics Committee of the Jagiellonian University (KBET/1072.6120.117.2018). All procedures were performed in accordance with the latest revision of the Declaration of Helsinki.

Statistical analysis

All data were analyzed with StatSoft Statistica v.13. The results are presented as mean ± standard deviation (SD), median and interquartile range (IQR) when appropriate. For the purposes of further analysis, the entire group of patients was divided into two groups. The study of categorical variables used the χ2 test of independence. The Shapiro-Wilk test was used to check for normal distribution of data and Student’s t-test was used for normally distributed quantitative data. For non-normally distributed quantitative variables, the Mann-Whitney U test was used. Results were considered statistically significant when the p-value was found to be less than 0.05.

Results

No intra-operative tumor ruptures were reported regardless of the study group, and the histopathological examination confirmed radical resection (R0 margins) for all patients. The clinical and pathomorphological features of the removed tumors are shown in Table III.

Table III

Clinical and pathomorphological features of the removed tumor

ParameterN (%)
Symptoms:
 Pain25 (36.8)
 Nausea10 (14.7)
 Vomiting2 (2.9)
 Weight loss5 (7.4)
 Heartburn3 (4.4)
 Bleeding of GI tract18 (26.5)
 Asymptomatic15 (22.1)
Immunohistochemical phenotype:
 CD 117 +66 (97.1)
 CD 34 +48 (70.6)
 DOG1 +18 (26.5)
 SMA +6 (8.8)
 Desmin +5 (7.4)
 S100 +3 (4.4)
 PKC theta +1 (1.5)
Size:
 Tumor ≤ 5 cm46 (67.6)
 Tumor > 5 cm22 (32.4)
GISTs confirmed before operation:
 Yes20 (29.4)
 No48 (70.6)

None of the patients who underwent laparoscopic treatment required subsequent open surgery. No deaths were reported in the 30-day post-operative period. Patients in group 1 (treated laparoscopically) had a significantly shorter length of hospital stay, less intra-operative blood loss, and fewer perioperative complications (13% vs. 41%) compared to group 2 (those who underwent open surgery). Short-term outcomes of treatment are shown in Table IV. Two patients required reoperation (both from group 1). In one of these patients, bleeding from the short gastric vessels was observed in the postoperative period. The other patient had symptoms of obstruction of the gastrointestinal tract due to narrowing of the stomach by the staple line at the location of the tumor. The remaining complications in either study group were not sufficiently serious to require surgical intervention (grade I and II in the Clavien-Dindo classification). Two patients from group 1 were rehospitalized – one due to suspected bleeding from the upper gastrointestinal tract (eventually ruled out), and another due to a small fluid collection in the vicinity of the stomach in the post-operative period (managed conservatively).

Table IV

Short-term outcomes of treatment

ParameterGroup 1Group 2P-value
Length of hospital stay, median (IQR) [days]3 (3–5)9 (8–11)< 0.0001
Operative time, median (IQR)100 (70–120)95 (80–150)0.1934
Intraoperative blood loss, median (IQR)25 (15–50)175 (100–205)< 0.0001
Patients without complications, n (%)40 (87.0)13 (59)0.0034
Clavien-Dindo 1, n (%)3 (6.5)2 (9.1)
Clavien-Dindo 2, n (%)1 (2.2)7 (31.9)
Clavien-Dindo 3, n (%)2 (4.3)

The mean post-operative follow-up for all patients in the study was 57 months (6–160 months). During this period, 4 patients (3 from group 1 and 1 from group 2) died for reasons unrelated to the primary disease. None of the patients who underwent a laparoscopic procedure received adjuvant treatment with tyrosine kinase inhibitors in the postoperative period, and none of them experienced any symptoms indicating the recurrence of the tumor in the follow-up period. In the group treated via open surgery, 5 patients were diagnosed with metastatic liver tumors (median time before recurrence was 22 months). These patients were treated with imatinib. During this treatment, no progression of the condition was observed for any of the patients.

Discussion

The comparison of post-operative data for patients with gastric GISTs showed that laparoscopic surgery was associated with significantly less blood loss, shorter hospitalization time, and a lower number of complications. Although nearly one third of the tumors were larger than 5 cm, both laparoscopic and conventional surgery resulted in radical resection, as confirmed by macroscopic assessment and histological examination.

The term gastrointestinal stromal tumors (GISTs) was introduced in 1983 by Mazur and Clark [1]. They originate from the precursors of cells of Cajal [11]. They are typically characterized by the expression of CD117, which is observed for 95% of these tumors. Other markers associated with GISTs include CD34, DOG1 and – less frequently – S100, SMA or desmin [12]. In the present study, CD117 expression was observed for 97.1% of the patients, while CD34 expression was found for 70.1% of them. The expression of the remaining markers was much less frequent. As per the current guidelines, the determination of these markers is key to the proper diagnosis of GISTs. In questionable cases, it is recommended that the KIT and PDGFRA genes be checked for mutation; this is especially significant in the case of GIST tissue negative for CD117 [9]. It should be emphasized that genetic examinations have an increasingly important role in diagnostics and treatment of many types of neoplasms [13].

Gastrointestinal stromal tumors can be excised with a small margin of healthy tissue without lymphadenectomy because they infrequently metastasize to lymph nodes (fewer than 3% of cases based on the available literature data [6, 7]). This makes minimally invasive techniques particularly suitable for the removal of GISTs, especially gastric ones. The first procedure of this type was performed more than 25 years ago [8]. Laparoscopy is currently a well-established method of treatment of small gastric GISTs [9]. There is a widespread opinion that if the team has adequate experience and will exercise sufficient care to maintain sufficient tumor-free margins during resection, the size of the tumor itself does not exclude the use of minimally invasive procedures [14, 15]. Its advantages over open surgery, including a lower post-operative pain level, earlier mobilization of the patient and shorter length of hospital stay, are well known [16]. This also applies to the patients in the present study, in whom laparoscopy was associated with a shorter hospital stay and reduced intra-operative blood loss. Similar observations were also made by other authors [17, 18]. When analyzing the results of laparoscopic treatment, the number and type of complications seem to be key factors. According to the literature, complication rates for this method range from several to a dozen or so percent, pulmonary complications (pneumonia, pulmonary embolism) being the most frequently reported type [3, 17]. In the present study, perioperative complications were reported for 13% of the patients who underwent laparoscopic surgery (group 1). This rate was significantly lower than in the group treated via open surgery (41%). It should be emphasized that the vast majority of all complications were grade I and II in the Clavien-Dindo classification and did not require surgical intervention; only two patients from group 1 had grade III complications and required reoperation. However, it is important to underline that tumors removed in patients from group 2 were larger and had higher potential for malignancy, which might have affected the complication rate in this group.

In the case of GIST removal, the rate of conversion from laparoscopy to laparotomy appears to be low. In their paper, Roggin and Posner present a review of results from five reports on the laparoscopic treatment of GISTs. According to this source, the conversion rates range from 0 to 6.5% [3]. In the present study, not a single case of conversion to laparotomy was found. At the same time, no intra-operative tumor rupture occurred, a noteworthy result given the fact that tumor rupture is a very significant prognostic factor for the recurrence of GIST. It appears that this complication can be avoided provided that the appropriate surgical technique is applied and the tissues are dissected in a sufficiently careful manner [19].

The analysis of a significant amount of data revealed no statistically significant differences in the 5-year survival rates of patients treated with either of these techniques [20, 21]. In the present study, the median post-surgery follow-up was just under 5 years. The survival rate in the group treated via laparoscopy was 93.4%. None of the three deaths in the study group was due to neoplasm. Kim et al. reported a 5-year survival rate of 98.6% and 94.8% of patients without progression of the disease. None of the patients who underwent laparoscopic surgery received adjuvant treatment with tyrosine kinase inhibitors, and no recurrences were observed. Adjuvant therapy with imatinib is recommended in the case of GISTs with a very high risk of recurrence [9, 22]. Two patients treated laparoscopically met inclusion criteria for adjuvant treatment, but did not receive it due to advanced age and comorbidities. These patients died during the follow-up period for reasons unrelated to the progression of GIST. In the group analyzed in this study, GIST metastasized to the liver in five patients treated with open surgery (incidence of 22.7%). In all these patients GIST had a high risk of relapse, which was more frequently observed in the group of patients undergoing laparotomy. All these patients received imatinib after the diagnosis of progression and had stable disease at the end of the 5-year follow-up.

Conclusions

Laparoscopy in the treatment of gastric GIST has similar efficacy as the classical open surgery. Minimally invasive procedures have unquestionable advantages, including decreased blood loss, reduced risk of complications, and shorter hospital stay. The team’s experience seems to be the most important factor reducing the incidence of complications and enabling safe extension of the use of laparoscopy to the treatment of oncological patients.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Mazur MT, Clark HB , authors. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983. 7:p. 507–19

2 

Lim KT, Tan KY , authors. Current research and treatment for gastrointestinal stromal tumors. World J Gastroenterol. 2017. 23:p. 4856–66

3 

Roggin KK, Posner MC , authors. Modern treatment of gastric gastrointestinal stromal tumors. World J Gastroenterol. 2012. 18:p. 6720–8

4 

Al-Kalaawy M, El-Zohairy MA, Mostafa A, et al. , authors. Gastrointestinal stromal tumors (GISTs), 10-year experience: patterns of failure and prognostic factors for survival of 127 patients. J Egypt Natl Canc Inst. 2012. 24:p. 31–9

5 

Walędziak M, Różańska-Walędziak A, Kowalewski PK, et al. , authors. Bariatric surgery and incidental gastrointestinal stromal tumors – a single-center study: VSJ Competition, 1(st) place. Videosurgery Miniinv. 2017. 12:p. 325–9

6 

Zhao X, Yue C , authors. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012. 3:p. 189–208

7 

Sicklick JK, Lopez NE , authors. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors. J Gastrointest Surg. 2013. 17:p. 1997–2006

8 

Lukaszczyk JJ, Preletz RJ Jr , authors. Laparoscopic resection of benign stromal tumor of the stomach. J Laparoendosc Surg. 1992. 2:p. 331–4

9 

ESMO/European Sarcoma Network Working Group , author. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014. 25 Suppl 3:p. iii21–6

10 

Clavien PA, Barkun J, de Oliveira ML, et al. , authors. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009. 250:p. 187–96

11 

Miettinen M, Lasota J , authors. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001. 438:p. 1–12

12 

Rubin BP, Blanke CD, Demetri GD, et al. , authors. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med. 2010. 134:p. 165–70

13 

Szeliga J, Sondka Z, Jackowski M, et al. , authors. NOD2/CARD15 polymorphism in patients with rectal cancer. Med Sci Monit. 2008. 14:p. CR480–4

14 

Smolarek S, Pomeroy E, Kinnarney F, et al. , authors. Laparoscopic resection of large gastric gastrointestinal stromal tumours. Videosurgery Miniinv. 2016. 11:p. 31–7

15 

Kermansaravi M, Rokhgireh S, Darabi S, et al. , authors. Laparoscopic total gastrectomy for a giant gastrointestinal stromal tumor (GIST) with acute massive gastrointestinal bleeding: a case report. Videosurgery Miniinv. 2017. 12:p. 306–10

16 

Kinoshita T, Shibasaki H, Oshiro T, et al. , authors. Comparison of laparoscopy-assisted and total laparoscopic Billroth-I gastrectomy for gastric cancer: a report of short-term outcomes. Surg Endosc. 2011. 25:p. 1395–401

17 

Chen QF, Huang CM, Lin M, et al. , authors. Short- and long-term outcomes of laparoscopic versus open resection for gastric gastrointestinal stromal tumors: a propensity score-matching analysis. Medicine (Baltimore). 2016. 95:p. e3135

18 

Goh BK, Goh YC, Eng AK, et al. , authors. Outcome after laparoscopic versus open wedge resection for suspected gastric gastrointestinal stromal tumors: a matched-pair case-control study. Eur J Surg Oncol. 2015. 41:p. 905–10

19 

Milone M, Elmore U, Musella M, et al. , authors. Safety and efficacy of laparoscopic wedge gastrectomy for large gastrointestinal stromal tumors. Eur J Surg Oncol. 2017. 43:p. 796–800

20 

Kim KH, Kim MC, Jung GJ, et al. , authors. Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible? World J Surg Oncol. 2012. 10:p. 230

21 

Ye L, Wu X, Wu T, et al. , authors. Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors. PLoS One. 2017. 12:p. e0177193

22 

Rutkowski P, Gronchi A , authors. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors. Oncologist. 2013. 18:p. 689–96

Copyright: © 2019 Fundacja Videochirurgii This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
  
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.